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ABSTRACT
The interaction between tumor cells and their microenvironment is an essential 
aspect of tumor development. Therefore, understanding how this microenvironment 
communicates with tumor cells is crucial for the development of new anti-cancer 
therapies. MicroRNAs (miRNAs) are small non-coding RNAs that inhibit gene 
expression. They are secreted into the extracellular medium in vesicles called 
exosomes, which allow communication between cells via the transfer of their 
cargo. Consequently, we hypothesized that circulating endothelial miRNAs could be 
transferred to tumor cells and modify their phenotype. Using exogenous miRNA, we 
demonstrated that endothelial cells can transfer miRNA to tumor cells via exosomes. 
Using miRNA profiling, we identified miR-503, which exhibited downregulated levels 
in exosomes released from endothelial cells cultured under tumoral conditions. 
The modulation of miR-503 in breast cancer cells altered their proliferative and 
invasive capacities. We then identified two targets of miR-503, CCND2 and CCND3. 
Moreover, we measured increased plasmatic miR-503 in breast cancer patients after 
neoadjuvant chemotherapy, which could be partly due to increased miRNA secretion 
by endothelial cells. Taken together, our data are the first to reveal the involvement 
of the endothelium in the modulation of tumor development via the secretion of 
circulating miR-503 in response to chemotherapy treatment.
INTRODUCTION
The tumor microenvironment includes a variety 
of cell types: fibroblasts, immune and endothelial cells, 
pericytes, and local and bone marrow-derived cells, 
surrounded by matrix components [1]. The crosstalk of this 
microenvironment with tumor cells is essential for tumor 
development, adaptation and metastasis formation [2]. 
Moreover, the blood supply plays a crucial role in cancer 
progression, allowing access to oxygen and nutrients that 
support tumor growth and eliminate metabolic waste. 
Thus, angiogenesis, the process by which new blood 
vessels arise from preexisting ones, is a crucial step in 
the progression of tumor development and metastases 
dissemination, and the blockade of angiogenesis is a 
promising strategy for the development of new cancer 
therapies [3]. However, drugs that inhibit tumor blood 
vessel formation by blocking the VEGF pathway have 
presently produced limited improvement in the clinical 
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setting [4]. Consequently, a better understanding of 
the interactions between cancer cells and the tumor 
microenvironment is necessary to unravel the complexity 
of tumor physiology and to limit the development of 
resistance mechanisms during anti-cancer treatments.
MicroRNAs (miRNAs) are small non-coding RNAs 
that are essential for the regulation of various physiological 
and pathological processes, including development, 
differentiation, proliferation and cancer [5,6]. These 
transcripts bind to the 3’ untranslated regions (UTRs) 
of messenger RNAs to either induce their degradation 
or inhibit their translation into proteins [7,8]. Cell-free 
miRNAs were found inside exosomes within biological 
fluids a few years ago [9,10]. Exosomes are small 
vesicles, ranging from 30 to 100 nm in size, composed 
of RNAs, microRNAs, and soluble and membranous 
proteins [11,12]. There is accumulating evidence that these 
organelles play a key role in intercellular communication 
via the transfer of their molecular contents [13–15]. 
Furthermore, recent findings demonstrate that circulating 
miRNAs are promising biomarkers for the diagnosis of 
several pathologies, demonstrating the notable abilities 
to discriminate between cancer types and stages and to 
monitor treatment responses [16–18].
Several studies have demonstrated that 
tumor exosomes are able to modulate the tumor 
microenvironment by activating angiogenesis, promoting 
the formation of cancer-associated fibroblasts (CAFs) 
and modulating the immune response [19–22]. However, 
little information is known regarding the role of exosomes 
derived from cells of the tumor microenvironment on the 
regulation of tumor cell metabolism. In the present study, 
we examined the potential transfer of miRNAs from 
endothelial to tumor cells via exosomes and their role 
in tumor behavior. We identified the endothelial miRNA 
miR-503, the expression of which is regulated by breast 
cancer neoadjuvant chemotherapy and which is able to 
inhibit tumor cell proliferation and invasion.
RESULTS
Endothelial exosomes allow the transfer of 
miRNAs to tumor cells
To investigate the role of circulating endothelial 
miRNAs on tumor cell physiology, we prospectively 
isolated and characterized exosomes from human 
umbilical vein endothelial cells (HUVECs). As 
demonstrated by dynamic light scattering, exosomes 
from endothelial cells show the typical size range of these 
vesicles, with a maximum peak at approximately 95 nm 
(Fig. 1A). Flow cytometry analysis also confirmed the 
presence of two well-known exosomal markers, CD63 
and CD9, on the exosome surface (Fig. 1B-C). Because 
the membranous protein composition of the exosomes is 
representative of the originating cells, we compared the 
presence of endothelial markers on HUVECs and HUVEC 
exosomes. As expected, both compartments presented a 
similar composition of markers, including αvβ3 integrins, 
CD31, CD105, E-selectin, ICAM-1, VCAM-1 and 
VE-cadherin. However, VEGFR2, which was strongly 
expressed on HUVECs, was not found on exosomes (Fig. 
1D and Fig. S1A-P). In addition, electron microscopy 
visualization of the exosomes also revealed a characteristic 
cup-shaped morphology, with a diameter of approximately 
100 nm. Furthermore, immunogold labeling was positive 
for the exosome marker CD63 and the endothelial marker 
CD105 (Fig. 1E).
Next, using an exogenous mouse miRNA that is 
not conserved in humans, mmu-miR-298, we sought to 
investigate the ability of endothelial cells to transfer 
miRNAs to human tumor cells. The miRNA was 
overexpressed in HUVECs, and the transfection efficiency 
was monitored using qRT-PCR (Fig. S1Q). Transfected 
HUVECs were then placed in a transwell coculture system 
with the cells separated by a membrane with 0.2-µm pores 
to prevent the transfer of miRNAs from other vesicles. 
This assay was applied to four tumor cell lines (lung 
carcinoma: A549, colorectal carcinoma: HCT116, breast 
adenocarcinoma: MDA-MB-231, and glioblastoma: U87) 
(Fig. 1F). Whereas HCT116 cells presented markedly low 
levels of mmu-miR-298, the three other tumor cell lines 
showed significant incorporation of the exogenous miRNA 
after 48 h. Exosomes were also purified from endothelial 
cells overexpressing mmu-miR-298, and the presence of 
the miRNA in exosomes was assessed using qRT-PCR 
(Fig. S1R). In addition, mmu-miR-298- and control-
loaded exosomes were incubated with the various tumor 
cell lines. As observed in the coculture system, mmu-
miR-298 was detected in all cell lines, but HCT116 cells 
still displayed reduced transfer levels (Fig. 1G). 
To study the interaction of endothelial exosomes 
with tumor cells, we labeled exosomes with the fluorescent 
lipid dye PKH67 and monitored uptake by the four tumor 
cell lines. Fluorescence microscopy revealed that all 
of the cell lines took up the exosomes, but the uptake 
by HCT116 cells was less pronounced (Fig. 1I). This 
observation was confirmed via flow cytometry (Fig. 1H). 
Notably, the exosome incorporation profile was similar to 
the mmu-miR-298 levels transferred via either coculture 
or endothelial exosomes, suggesting a major contribution 
by exosomes in the transfer of miRNAs. Moreover, the 
variation in uptake efficiencies between different tumor 
cell types strongly suggests the selective incorporation of 
endothelial exosomes. To further visualize the mechanism 
of exosome capture, we monitored exosome uptake over 
time using electron microscopy. For that experiment, we 
chose the MDA-MB-231 cell line, as these cells displayed 
a high level of exosome incorporation. If no exosomes 
were added to tumor cells, no specific patterns could be 
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observed inside the endocytic vesicles. However, after 
2 hours, entities with the characteristic cup shape of 
exosomes could already be observed inside the endosomes; 
these entities accumulated over time, as observed after 8 
and 24 h (Fig. 1J). These data demonstrate that endothelial 
exosomes are taken up by tumor cells via endocytosis to 
allow the intercellular transfer of miRNAs.
The tumor environment modifies the export of a 
subset of endothelial miRNAs
Several studies have shown that miRNAs can be 
transferred from tumor cells to modulate angiogenesis. 
Here, we speculated that the exchange could also occur 
in the opposite direction. We hypothesized that tumor 
cells might elicit an anti-tumor response through the 
secretion of miRNAs from the endothelium. We thus 
Figure 1: Endothelial exosomes can transfer miRNAs to tumor cells. (A) Dynamic light scattering analysis of HUVEC exosomes 
(max = 94.93). Flow cytometry analysis of HUVEC exosomes immunolabeled for (B) CD9 and (C) CD63. (D) Table summarizing the 
levels of endothelial markers in HUVECs and HUVEC exosomes, measured using flow cytometry. (E) Electron micrographs of HUVEC 
exosomes labeled with CD63 and CD105, scale bars = 50 nm. (F) MiR-298 levels evaluated using qRT-PCR in cocultures either of tumor 
cells with HUVECs transfected with pre-miR-control or pre-miR-298 or (G) of tumor cells incubated with exosomes from HUVECs 
transfected with pre-miR-control or pre-miR-298. (H) Flow cytometry analysis of the uptake of exosomes (labeled with the green fluorescent 
PHK67 membrane linker) by tumor cells. (I) Fluorescence microscopy detection of the uptake of PHK67-labeled exosomes by tumor cells 
(DAPI, blue), scale bars = 25 µm. (J) Electron micrographs of MDA-MB-231 cell sections showing vesicles (arrows); after incubation 
with HUVEC exosomes for 0, 2, 8 and 24 hours, MDA-MB-231 cells showed larger multivesicular vesicles containing exosomes, scale 
bars = 100 nm. All data are the mean ± SD (n ≥ 3). *P < 0.05, **P < 0.01 and ***P < 0.001 vs. the respective control. Additionally, see 
Supplemental Figure 1.
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investigated the miRNA content of endothelial exosomes 
to identify miRNAs that could modify tumor growth. We 
first performed miRNA expression profiles using PCR 
panels (Exiqon) to compare between HUVECs and their 
exosomes. As observed in other studies [9,23], most of 
the miRNAs were expressed at similar levels in cells and 
exosomes, although some were detected only in cells (10 
miRNAs) or in exosomes (16 miRNAs) (Fig. 2A-B and 
Fig. S2A). To identify endothelial miRNAs that could 
affect tumor development, we then profiled the miRNA 
content of exosomes from HUVECs cultured in a basal 
medium or in a tumor-mimicking medium enriched with 
growth factors. Basal medium was composed of 5% serum 
whereas tumoral medium contained a mix of growth 
factors optimized for HUVECs culture supplemented 
everyday with high doses of VEGF (50 ng/ml) and bFGF 
(20 ng/ml). Indeed, these two molecules are well-known 
activators of tumor angiogenesis [24]. As measured by 
Figure 2: The tumor environment modifies the export of a subset of endothelial miRNAs. (A) Dot plot of miRNA levels 
in HUVECs compared with HUVEC exosomes. (B) Diagram of miRNAs common and specific to HUVECs and HUVEC exosomes. (C) 
Exosome levels measured by protein quantification from the conditioned medium of HUVECs cultured in basal and tumor-mimicking 
medium conditions. (D) Volcano plot of fold changes (log
2
 values) and probability values (-log
10
) for individual miRNAs in the exosomes 
from HUVECs cultured under basal and tumoral conditions. (E) Table of the three most upregulated and downregulated miRNAs under 
tumoral vs. basal conditions. MiR-146a (F) and miR-503 (G) levels, evaluated by qRT-PCR in HUVEC exosomes cultured under tumoral 
or basal conditions. MiR-146a (H) and miR-503 (I) levels, evaluated by qRT-PCR in HUVECs cultured in tumoral or basal conditions. 
All data are the mean ± SD (A-E, n = 2; F-I, n = 3). *P < 0.05, **P < 0.01 and ***P < 0.001 vs. the respective control. Additionally, see 
Supplemental Figure 2.
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protein quantification, the first notable observation was 
the radical decrease in the level of exosome secretion 
in HUVECs cultured in the tumor medium compared 
with those cultured in the basal medium (Fig. 2C). Only 
miRNAs that were detected in all samples, displayed 
a variation lower than 2 between replicates and an 
individual Ct value lower than 40 were considered for 
further analysis. These criteria led to the selection of 204 
miRNAs (Fig. S2B). When comparing the miRNA ratio 
derived from exosomes and HUVECs, 108 miRNAs were 
found to be modulated in HUVEC-derived exosomes by 
at least twofold (Fig. 2 D-E and Supplemental Table 1). 
As shown in the volcano plot, the 3 most upregulated 
miRNAs were miR-502-5p, miR-744 and miR-373*, 
whereas the most downregulated miRNAs were miR-
146a, miR-205 and miR-503 (Fig. 2D-E). For further 
investigation, we examined the 3 most downregulated 
miRNAs, which, according to our hypothesis, might 
exhibit antitumor properties. The decreased miR-146a 
and miR-503 levels in tumoral and basal exosomes were 
confirmed using TaqMan microRNA assays; however, we 
were unable to confirm the alteration in miR-205 levels 
(Fig. 2F-G). Interestingly, we observed that miR-146a 
levels were also decreased in the exosome-producing 
endothelial cells, whereas miR-503 levels were not 
modified under tumor-mimicking conditions (Fig. 2H-I). 
We then decided to further study miR-503 because this 
miRNA undergoes a selective export mechanism under 
tumor-mimicking conditions. In addition, miR-503 is a 
member of the extended miR-16 family, which has been 
widely described in the literature as an anti-tumor miRNA 
that regulates cell cycle progression and the proliferation 
status of cells [25–27].
Endothelial miR-503 impairs tumor growth in 
vitro
To investigate the impact of miR-503 on tumor 
growth, we performed gain- and loss-of-function studies. 
MDA-MB-231 cells were transfected with either pre- 
or anti-miR-503, and the transfection efficiency was 
monitored using qRT-PCR (Fig. S3A). We used MDA-
MB-231 constitutively expressing luciferase to quantify 
the proliferation in a coculture system by measuring 
the luminescence. Moreover, tumor cell invasion was 
assessed by quantifying the sprouting of tumor spheroids 
in a 3D collagen matrix. Increasing miR-503 levels 
Figure 3: Endothelial miR-503 impairs tumor growth in vitro. (A) Invasion level of MDA-MB-231 cells transfected with 
pre-miR-control or pre-miR-503 and with anti-miR-control or anti-miR-503. (B) Luminescence quantification of MDA-MB-231 cells 
transfected with pre-miR-control or pre-miR-503 and with anti-miR-control or anti-miR-503. (C) MiR-503 levels, measured by qRT-PCR 
in MDA-MB-231 cells incubated with 5 µg of HUVEC exosomes for 24 h. (D) Invasion level of MDA-MB-231 cells transfected with 
anti-miR-control or anti-miR-503 and cocultured with HUVECs transfected with pre-miR-control or pre-miR-503. (E) Luminescence 
quantification of MDA-MB-231 cells transfected with anti-miR-control or anti-miR-503 and cocultured with HUVECs transfected with 
pre-miR-control or pre-miR-503. (F) Luminescence quantification of MDA-MB-231 cells incubated with exosomes from HUVECs 
transfected with pre-miR-control or pre-miR-503. Additionally, see Supplemental Figure 3.
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via the transfection of miRNA mimics (pre-miRs) in 
MDA-MB-231 cells decreased both cell proliferation 
and invasion. Conversely, inhibition of miR-503 via the 
transfection of miR-503 antisense LNAs (anti-miRs) 
resulted in increased levels both of these processes 
compared with those of the control (Fig. 3A-B). Moreover, 
the effects of modulating miR-503 on tumor proliferation 
and invasion were confirmed by measuring BrdU 
incorporation and performing Boyden chamber assays, 
respectively (Fig. S3B-C). 
We next sought to explore the effect of endothelial-
derived miR-503 on MDA-MB-231 cells. For this 
purpose, HUVECs were transfected with pre-miR-503, 
and the transfection efficiency was monitored using qRT-
PCR (Fig. S3D). The effective transfer of the miRNA was 
then assessed using endothelial exosomes loaded with 
miR-503. Upon incubation of miR-503-loaded exosomes 
with MDA-MB-231 cells, we observed increased miRNA 
levels in the cells using qRT-PCR (Fig. 3C). We next 
investigated whether miR-503 secreted from endothelial 
cells could modify the phenotype of MDA-MB-231 cells. 
HUVECs overexpressing miR-503 were cocultured with 
MDA-MB-231 cells, which led to reduced tumor cell 
proliferation and invasion compared with those under 
control conditions (Fig. 3D-E). Importantly, the addition 
of anti-miR-503 into tumor cells rescued the effects of 
endothelial miR-503 in both functional assays. This 
observation suggest that miR-503 is the main effector 
of tumor cell proliferation and invasion inhibition in 
endothelial exosomes. To confirm that these effects 
were caused by the transfer of endothelial miR-503 via 
exosomes, we treated MDA-MB-231 cells with miRNA-
loaded HUVEC exosomes. This treatment also resulted in 
reduced MDA-MB-231 proliferation compared with the 
cells treated with mock HUVEC exosomes (Fig. 3F). 
MiR-503 inhibits CCND2 and CCND3 expression 
of MDA-MB-231
To explore the molecular mechanism responsible 
for the inhibition of tumor cell proliferation and invasion 
by miR-503, we searched for target genes of the miRNA 
involved in those mechanisms. We used a computational 
approach involving the Targetscan algorithm (http://www.
targetscan.org/) to obtain a list of genes predicted to be 
targets of miR-503. We then used the STRING algorithm 
(http://string-db.org/), which creates a network between 
Figure 4: MiR-503 inhibits CCND2 and CCND3 expression of MDA-MB-231. Quantification of mRNA levels according to 
qRT-PCR of (A) CCND2 and (B) CCND3 in MDA-MB-231 cells transfected with pre-miR-503 or pre-miR-control and with anti-miR-
control or anti-miR-503 and starved for 36 h. (C) Western blotting of CCND2 and CCND3 in MDA-MB-231 cells transfected with pre-
miR-503 or pre-miR-control and with anti-miR-control or anti-miR-503 and starved for 36 h. (D) Luciferase activity from the CCND2 
3′-UTR WT reporter plasmid and mutated NRAS 3′-UTR reporter plasmid cotransfected into MDA-MB-231 cells with pre-miR-control 
or pre-miR-503 after 24 hours. (E) Invasion levels of MDA-MB-231 cells transfected with siRNAs targeting CCND2 and CCND3. (F) 
Luminescence quantification of MDA-MB-231 cells transfected with siRNAs targeting CCND2 and CCND3. *P < 0.05, **P < 0.01 and 
***P < 0.001 vs. the respective control. ###P < 0.001 vs. miR-503-exosomes with anti-miR-control. Additionally, see Supplemental Figure 4.
Oncotarget7www.impactjournals.com/oncotarget
proteins that have functional or physical interactions, 
to identify associations between predicted targets of 
miR-503. We observed the presence of a large cluster of 
proteins that influence cell cycle progression and pathways 
that regulate the proliferation/apoptosis status of cells 
(Fig. S4C). Using qRT-PCR, we tested a subset of miR-
503 target genes that displayed many links with each other 
to identify the genes responsible for the observed anti-
tumor phenotype. From this subset of genes, we identified 
two targets of miR-503, CCND2 and CCND3, which 
are downregulated at the RNA and protein levels upon 
overexpression of the miRNA (Fig. 4A-C). Importantly, 
inhibiting endogenous miR-503 using anti-miR 
transfection led to increased CCND2 and CCND3 protein 
levels. The interaction sites of miR-503 and the CCND2 
and CCND3 3’-UTRs are pictured in Fig S4D. Notably, 
expression of the homologue CCND1 was not affected 
by miR-503 even though this gene is a validated target of 
miR-503 (Fig. S4A-B). Because CCND2 has never been 
described as a target of miR-503, we analyzed whether 
the miRNA directly interacts with its 3’-UTR. Indeed, 
there are 3 binding sites for miR-503 in the CCND2 3’-
UTR: one 8-mer site and two 7-mer-1A sites. We therefore 
constructed a luciferase reporter vector that encoded the 
3’-UTR of CCND2 downstream of the luciferase coding 
sequence. Reduced luciferase activity was observed 
in MDA-MB-231 cells transfected with the vector; 
these cells were also observed to overexpress miR-503 
compared with that of the control (Fig. 4D). Moreover, 
when the sequences that bind the seed region of miR-503 
were mutated in the CCND2 3’-UTR, the miRNA was no 
longer able to inhibit translation of the luciferase mRNA, 
leading to normalized luminescence levels. 
We next determined whether the inhibition of 
CCND2 and CCND3 was responsible for the inhibition of 
tumor cell proliferation and invasion observed upon miR-
503 modulation. Indeed, silencing CCND2 and CCND3 
in MDA-MB-231 cells with siRNA led to decreased 
proliferation and invasion (Fig. 4E-F). Taken together, 
these results demonstrate that endothelial-derived miR-
503 induces the inhibition of tumor cell proliferation and 
invasion via inhibition of CCND2 and CCND3.
Neoadjuvant chemotherapy increases circulating 
miR-503 levels
To study the potential endothelial release of miR-
503 during cancer, we analyzed the plasmatic miR-503 
levels in breast cancer patients subjected to various 
therapies. Interestingly, we observed increased miR-503 
levels in patients receiving neoadjuvant chemotherapy 
treatment, whereas no changes were observed in patients 
treated only with surgery (Fig. 4A-B and D-E). To 
more deeply investigate the influence of neoadjuvant 
chemotherapy, miR-503 levels were analyzed in tumor 
biopsies and in residual tumors of patients subjected to 
this treatment and presenting an incomplete pathological 
response. Surprisingly, no changes in the miR-503 
levels were observed before treatment or after post-
chemotherapy surgery (Fig. 4C and F). This observation 
favors the view that the increased miR-503 levels in 
the circulation after chemotherapy do not come from 
the tumor. Thus, we decided to investigate whether 
endothelial cells could be responsible for the increased 
miR-503 levels upon neoadjuvant chemotherapy. We 
treated endothelial cells with both chemotherapeutic 
agents (epirubicin and paclitaxel) used in the treatment 
and analyzed the consequences on miR-503 expression 
and exosome secretion using qRT-PCR. We first observed 
a drastic increase in exosome production in endothelial 
cells treated with the chemotherapeutic agents; this effect 
was more pronounced with paclitaxel than with epirubicin 
treatment (Fig. 4G). Moreover, we observed increased 
miR-503 levels in exosomes following epirubicin and 
paclitaxel treatments compared with control conditions, 
whereas decreased levels were observed in exosome-
producing HUVECs (Fig. 4H-I). These data suggest 
that the elevated circulating miR-503 levels observed in 
patients after neoadjuvant chemotherapy could originate 
in part from exosome modification and miR-503 secretion 
by endothelial cells.
DISCUSSION
Over the past few years, exosomes have emerged 
as important players in intercellular communication. 
Notably, several studies have demonstrated the role of 
tumor exosomes in regulating major processes of tumor 
progression, such as angiogenesis, immune modulation 
and metastasis dissemination. However, until now, the 
effects of exosomes secreted from endothelial cells on 
tumor cells has not been explored. Endothelial exosomes 
have been shown to induce several mechanisms, such as 
the regulation of angiogenesis in other endothelial cells 
[28,29] and the atheroprotective stimulation of smooth 
muscle cells [15]. It is well known that cells within 
the tumor microenvironment can act on tumor cells. 
In this context, a role for exosomes has emerged in the 
recent literature. For example, exosomes secreted from 
mesenchymal stem cells can regulate tumor growth, 
whereas exosomes from dendritic cells can induce tumor 
regression [30–32]. In this study, we demonstrate that 
endothelial cells, which are also important players in 
the tumor environment, produce exosomes that are able 
to transfer miRNAs to tumor cells. Our data reveal that 
this transfer involves endocytosis because incorporated 
exosomes are observed in endocytic vesicles inside tumor 
cells. 
An important finding of our work is the observation 
that the miRNA content of endothelial exosomes differs 
from that of the producing cells. This phenomenon has 
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been described in other studies and demonstrates that, at 
least in part, miRNAs can be selectively packaged into 
exosomes [9,23]. In addition, our profiling experiment also 
revealed that the miRNA content of exosomes is altered 
by the culture conditions. This experiment led to the 
identification of miR-503, the exosome levels of which are 
decreased under tumor conditions despite cellular levels 
being unaffected. Notably, miR-424, which belongs to 
the same cluster as miR-503, also showed reduced levels 
under the same conditions. MiR-503 is known to inhibit 
proliferation, migration and tube formation in endothelial 
cells under high-glucose stress conditions [33]. Moreover, 
miR-503 has been widely described in the literature as 
an anti-tumor miRNA that regulates the expression of 
key cell cycle proteins, such as CDC25A and cyclins D1 
and E1, as well as cell proliferation via E2F3 and PI3K 
regulation and the apoptosis status via BCL-2 inhibition 
[6,25–27,33,34]. Notably, miR-503 also prevents tumor 
Figure 5: Neoadjuvant chemotherapy increases circulating miR-503 levels. (A) The miR-503 ratio according to qRT-PCR in 
blood samples of breast cancer patients before and after neoadjuvant chemotherapy. (B) The miR-503 ratio according to qRT-PCR in blood 
samples of breast cancer patients before and after surgery. (C) The miR-503 ratio according to qRT-PCR in tumor biopsies and residual 
tumors of breast cancer patients. (D) Individual follow-up of miR-503 levels, evaluated by qRT-PCR, in blood samples of breast cancer 
patients before and after neoadjuvant chemotherapy. (E) Individual follow-up of miR-503 levels, evaluated by qRT-PCR, in blood samples 
of breast cancer patients before and after surgery. (F) Individual follow-up of miR-503 levels, evaluated by qRT-PCR, in tumor biopsies 
and residual tumors of breast cancer patients. (G) Exosome levels, measured by protein quantification, from the conditioned medium 
of HUVECs treated with paclitaxel and epirubicin for 24 h. (H) The miR-503 levels, evaluated by qRT-PCR, in HUVECs treated with 
paclitaxel and epirubicin for 24 h. (I) The miR-503 levels, evaluated by qRT-PCR, in exosomes from HUVECs treated with paclitaxel and 
epirubicin for 24 h. *P < 0.05, **P < 0.01 and ***P < 0.001 vs. the respective control.
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growth by interacting with the tumor microenvironment 
and reducing secretion of the proangiogenic factors FGF2 
and VEGF by tumor cells [35]. We obtained similar results 
by modulating the expression of miRNA in MDA-MB-231 
cells. The overexpression of miR-503 led to decreased 
tumor cell proliferation and invasion in multiple assays, 
whereas its inhibition presented opposite results. The role 
of endothelial miR-503 contained in exosomes has also 
been investigated by coculturing HUVECs overexpressing 
miR-503 with tumor cells. This manipulation also led to 
reduced proliferative and invasive properties, which could 
be reversed by adding anti-miR-503 to MDA-MB-231 
cells. During investigation of the mRNA targets of miR-
503 to explain these effects, we identified that miR-503 
regulated cyclins D2 and D3. Cyclin D3 is already a 
validated target of miR-503; however, the regulation of 
the cyclin D2 had not yet been demonstrated [26]. Overall, 
these data showed that endothelial cells cultured under 
tumoral conditions released miR-503, which can have 
antitumoral effects, into the medium.
Our human studies revealed a role for miR-503 
in response to neoadjuvant therapy. Plasmatic miR-
503 levels were elevated in breast cancer patients 
receiving neoadjuvant chemotherapy. As suggested by 
our in vitro data, the elevation of miR-503 in the blood 
after chemotherapy could originate, at least in part, 
from the increased secretion of miR-503 by endothelial 
cells following paclitaxel and epirubicin treatment. 
Because decreased miR-503 expression was observed in 
exosome-producing endothelial cells, it is likely that the 
chemotherapeutic agent promotes the transfer of miR-503 
to exosomes rather than the induction of its expression. 
A similar effect has been reported in endothelial cells 
submitted to ionizing radiation [36]. On the other hand, 
plasmatic levels of miR-503 of patients treated only with 
surgery, and tumor levels of miR-503 of patients under 
chemotherapy were not affected. Therefore, it is likely 
that endothelial circulating miR-503 would originate 
from the entire endothelium. As previously described 
by other studies, anthracyclines and taxanes induce an 
endothelial toxicity which also affects endothelial cells 
outside of the tumor [37]. Therefore, miR-503 might 
act as a stress-induced miRNA that is essential for cell 
cycle regulation. Its expression is increased upon serum 
starvation of mesenchymal stem cells and is modulated 
according to cell cycle progression [38,39]. Thus, we 
propose a model in which endothelial cells, in response 
to unfavorable conditions, such as chemotherapy or 
radiation treatment, release circulating miR-503 into the 
surrounding environment (Fig. 5). Endothelial exosomes 
loaded with miR-503 might then inhibit tumor growth 
by acting directly on tumor cells, thereby contributing 
to the direct effect of these therapies. To the best of our 
knowledge, this is the first report of a miRNA transferred 
from endothelial cells to tumor cells via exosomes. Our 
data also reveal the involvement of the endothelium in the 
modulation of tumor development upon chemotherapy 
treatment. In this context, miR-503 appears to be an 
antitumor miRNA secreted by endothelial cells that is 
able to regulate tumor cell proliferation and invasion 
via the inhibition of CCND2 and CCND3. This process 
might complement the direct effects of chemotherapy and 
thereby help the host fight the tumor.
Figure 6: Endothelial transfer of miR-503 elicit antitumor response during neoadjuvant chemotherapy. Endothelial cells 
treated with chemotherapeutic agents release more exosomes that contain more miR-503. MiR-503 loaded exosomes induce a reduction of 




The isolation and culture of HUVECs (passages 
6–11) were previously described [40]. A549 and U87 
cells were cultured in EMEM supplemented with 10% 
FBS. HCT116 cells were cultured in McCoy’s 5A medium 
supplemented with 10% FBS. MDA-MB-231 cells were 
cultured in DMEM 4500 supplemented with 10% FBS. 
Cell transfections and treatments
Pre-miRs (25 nM; Ambion) and anti-miRs (25 
nM; Exiqon) were transfected into HUVECs and MDA-
MB-231 cells using Dharmafect-4 (Dharmacon Research 
Inc.) according to the manufacturer’s instructions. 
CCND2, CCND3 and control siRNAs (20 nM) were 
transfected based on the calcium phosphate transfection 
method. Transfected HUVECs and MDA-MB-231 cells 
were plated in EGM2 or complete DMEM, respectively. 
After a 24-hour transfection, the cells were washed and 
kept in their media for an additional 48 or 72 hours. 
Functional assays were performed as described above.
Exosome purification 
Exosomes were isolated and purified from the 
supernatants of HUVEC cultures using the differential 
centrifugations. HUVECs were cultured in EGM2 medium 
containing exosome-depleted serum. After 72 h, the 
medium was collected and centrifuged at 2000 g for 15 
min at 4°C and then again at 12,000 g for 45 min at 4°C. 
Supernatants were then passed through a 0.22-μm filter 
(Millipore) and ultracentrifuged at 110,000 g for 90 min at 
4°C. The pellets were then washed with phosphate buffer 
saline (PBS), followed by a second ultracentrifugation 
at 110,000 g for 90 min at 4 °C, then resuspended in 
PBS. The protein levels of the exosome preparations 
were measured using the BCA Protein Assay kit (Pierce) 
following the manufacturer’s instructions.
PKH67 labeling of exosomes
Exosomes were labeled with PKH67 dye (Sigma) 
according to the manufacturer’s instructions, and 
incubated with cells for 24 h. The cells were then washed 
2 times with PBS and mounted on a slide for observation 
under a fluorescence microscope.
Dynamic light scattering
Exosomes were suspended in PBS at a concentration 
of 50 µg/mL, and analyses were performed with a 
Zetasizer Nano ZS (Malvern Instruments, Ltd.). Intensity, 
volume and distribution data for each sample were 
collected on a continuous basis for 4 min in sets of 3.
Flow cytometry 
Cells were first saturated for 30 min in PBS 
containing 5% BSA and incubated for 1 h at 4°C with 
the following antibodies: anti-αvβ3 integrin (Chemicon), 
anti-CD9 (Santa Cruz), anti-CD31 (Dako), anti-CD63 
(BD-Biosciences), anti-CD105 (Dako), anti-E-selectin 
(Abcam), anti-ICAM-1 (Abcam), anti-V-CAM1 (Abcam), 
anti-VE-Cadherin (Enzo Life Sciences) and anti-VEGFR2 
(Cell Signaling). Cells were then incubated with a biotin-
coupled secondary antibody for 30 min and then incubated 
with streptavidin-PE for 30 min before being analyzed 
on the FACSCalibur flow cytometer (BD Biosciences). 
Exosomes were incubated for 30 min with latex beads 
(Invitrogen), then the exosome-coated beads were 
subjected to the same steps.
Patients
Ethical approval was obtained from the Institutional 
Review Board (Ethical Committee of the Faculty of 
Medicine of the University of Liège) in compliance with 
the Declaration of Helsinki. Patients with newly diagnosed 
primary breast cancer were prospectively recruited at 
CHU of Liège (Liège, Belgium) from July 2011 to July 
2013. All patients signed a written informed consent form. 
This work consisted of a prospective study and did not 
influence the treatment of the enrolled patients; 29 patients 
were included in this study. Blood samples were collected 
into 9-mL EDTA-containing tubes. Plasma was prepared 
within 1 h by retaining the supernatant after double 
centrifugation at 4°C (10 min at 815 g and 10 min at 2500 
g), then stored at -80°C.
Seventeen patients with primary locally advanced 
breast cancer received neoadjuvant chemotherapy (NAC) 
with 3 or 4 courses of alkylating agents (cyclophosphamide 
or fluorouracil) and anthracycline-based chemotherapy 
(epirubicin) followed by 3 or 12 courses of tubulin-
binding agents (docetaxel or paclitaxel). Eight of these 
patients did not achieved pathological complete response 
(ypT0N0, following the AJCC-UICC classification) 
For those 8 non responders, 4-μm tumor slices from 
formalin-fixed paraffin-embedded (FFPE) tissues samples 
were obtained from diagnostic core-needle biopsies (2 
to 3 passes in the primary tumor) and the corresponding 
remaining tumor. The histological statuses of all 8 tissues 
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samples were established with hematoxylin and eosin 
staining of the FFPE sections by a pathologist.
Circulating miR-503 levels were also analyzed in a 
cohort of twelve primary breast cancer patients that did not 
receive any chemotherapy, and their plasma was collected 
8 days before and 3 months after surgery.
Electron microscopy of whole-mounted immuno-
labelled exosomes
Exosome were placed on Formvar-carbon coated 
nickel grids for 1 h, washed 3 times with PBS and fixed 
with 2% paraformaldehyde for 10 min. After 3 washes, 
grids were then incubated for 2 h with the following 
antibodies: anti-CD63 or anti-CD105. Exosomes were 
then washed 5 times and incubated with a 10 nm-gold 
labeled secondary antibody. They were washed 5 more 
times and post-fixed with 2.5% glutaraldehyde for 10 
min. Samples were contrasted using 2.5% uranyl acetate 
for 10 min followed by 4 washes and an incubation of 
10 min in lead citrate. Grids were finally washed 4 times 
in deionized water and examined with a JEOL JEM-1400 
transmission electron microscope at 80 kV.
Electron microscopy of exosome uptake in MDA-
MB-231
MDA-MB-231 cells were treated with exosomes 
(final concentration, 20 μg/mL) dissolved in PBS. After 0, 
2, 8 and 24 h pre-incubation, the MDA-MB-231 cells were 
washed with PBS and fixed in 2.5% glutaraldehyde/1% 
paraformaldehyde in 0.1 M PBS (pH 7.4) for 2 h at 4°C. 
Then, the cells were washed 3 times in PBS for 10 min at 
4°C and post-fixed for 30 min with 2% osmium tetroxide. 
After dehydration in graded ethanol, samples were 
embedded in Epon. Ultrathin sections were obtained with 
a Reichert Ultracut S ultramicrotome then contrasted with 
uranyl acetate and lead citrate. Observations were made 
with a JEOL JEM-1400 transmission electron microscope 
at 80 kV.
MicroRNA profiling
Total RNA was extracted with the miRNeasy kit 
(Qiagen) following the manufacturer’s protocol, and cel-
miR-39 and cel-miR-238 were spiked into the exosome 
samples. Reverse transcription was then performed 
using the miRCURY LNA™ Universal RT microRNA 
PCR, polyadenylation and cDNA synthesis kit (Exiqon, 
Denmark). Quantitative PCR was performed according to 
the manufacturer’s instructions on microRNA Ready-to-
Use PCR panel 1. The controls included reference genes, 
inter-plate calibrators run in triplicate (Sp3) and negative 
controls.
Cell coculture and functional assays
For cocultures, endothelial donor cells were seeded 
onto 6-well plates. After 8 hours, transwells were added, 
and tumor cells were seeded onto the inner part of the 
transwell membranes. After 48 h of incubation, tumor cells 
were collected and analyzed.
Proliferation assays
For the luminescence proliferation assay, MDA-
MB-231 cells were transfected or incubated with 
transfected HUVECs on a 24-well plate. After 48 h, 
150 µg/mL of luciferin was added per well, and the 
luminescence was quantified using the bioluminescent 
IVIS imaging system (Xenogen-Caliper). 
For the BrdU incorporation assay, MDA-MB-231 
cells were transfected and seeded into 96-well plates for 40 
h. BrdU was added for 8 h, and proliferation was assessed 
using the Cell Proliferation ELISA BrdU (colorimetric) kit 
(Roche) following the manufacturer’s instructions. 
Spheroid invasion assay
Spheroids were prepared as previously described 
[41]. Briefly, spheroids composed of transfected MDA-
MB-231 alone or with transfected HUVECs were allowed 
to form in 96-U-well suspension plates for 48 h. Spheroids 
were then collected and seeded for 48 h inside a 3D 
collagen matrix with culture medium. Pictures were taken 
to quantify the invasion level by measuring the area of 
invasion using ImageJ software.
Boyden chamber assay
Transfected MDA-MB-231 cells were seeded 
into 8-µm 24-well Boyden chambers (Transwell; Costar 
Corp) and subjected to cell invasion assays. The lower 
chamber was filled with 600 μL of complete DMEM, and 
transfected MDA-MB-231 cells were placed in 300 μL of 
free DMEM in the upper chamber and allowed to migrate 
for 4 h at 37°C. After fixation, cells were stained with 4% 
Giemsa and counted on the lower side of the membrane 
using ImageJ software. 
Chemotherapy treatment of endothelial cells
HUVECs were cultured in EGM2 supplemented 
with 1 µg/mL epirubicin or 20 ng/mL paclitaxel. After 
24 h, the medium was swapped with exosome-depleted 
medium, and the cells were cultured for 72 additional 
hours before being collected for exosome purification.
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Preparation of cell extracts and Western blot 
analysis 
Cells were washed with PBS and scraped 
into lysis buffer [50 mM Tris-HCl (pH = 7.5); 1% 
NP40; 0.5% sodium desoxycholate; 1 mM EDTA; 
protease inhibitor cocktail cOmplete Mini, EDTA free 
(Roche)] on ice. Insoluble cell debris was removed 
by centrifugation at 10,000 g for 15 min. Aliquots of 
protein-containing supernatant were stored at -20°C, and 
protein concentrations were measured using the BCA 
Protein Assay kit (Pierce) following the manufacturer’s 
instructions. 
Soluble cell lysates (50 μg) were resolved using 
SDS-PAGE (12%) and transferred to polyvinylidene 
fluoride membranes (Millipore). Blots were blocked 
overnight with 8% milk in Tris-buffered saline with 0.1% 
Tween 20 and probed for 1 h with the following primary 
antibodies: anti-CCND1 (Cell Signaling), anti-CCND2 
(Cell Signaling), anti-CCND3 (Cell Signaling), and 
anti-beta-tubulin (ab6046, Abcam). After 3 washes with 
Tris-buffered saline containing 0.1% Tween 20, antigen-
antibody complexes were detected with a peroxidase-
conjugated secondary antibody and the enhanced fluoro-
chemiluminescent system (ECL; Pierce Biotechnology). 
Quantifications were performed using ImageJ software 
and are presented in bar graphs normalized to the levels of 
the corresponding loading control (β-tubulin).
RNA extraction, miRNA and mRNA expression 
analysis using the TaqMan microRNA assay and 
quantitative real-time PCR analysis. 
Total RNA was extracted using the miRNeasy kit 
(Qiagen) following manufacturer’s protocol, and cel-
miR-39 and cel-miR-238 were spiked into exosome and 
plasma samples. 
TaqMan assays were used to assess miRNA 
expression. Briefly, 10 ng RNA was reverse transcribed 
into cDNA using the TaqMan microRNA Reverse 
Transcription kit and the TaqMan microRNA assay 
stem loop primers (Applied Biosystems). The resulting 
cDNAs were used for quantitative real-time PCR using 
the TaqMan microRNA assay and TaqMan universal 
PCR master mix reagents (Applied Biosystems). Thermal 
cycling was performed on an Applied Biosystems 7900 
HT detection system (Applied Biosystems). For the cells, 
the relative miRNA levels were normalized to 2 internal 
controls, RNU-44 or RNU-48. For the plasma and 
exosomes, the relative miRNA levels were normalized 
to the 2 spiked-in miRNAs: cel-miR-39 and cel-miR-238 
(Applied Biosystems). 
For mRNA expression analysis, RNA was 
extracted using the miRNeasy kit (Qiagen) according 
to the manufacturer’s protocol. cDNA synthesis was 
performed with 1 μg of total RNA and the iScript cDNA 
Synthesis kit (BioRad), according to the manufacturer’s 
instructions. The resulting cDNA transcripts (20 ng) 
served as the template for quantitative real-time PCR 
using the SYBR green method (Roche Applied Sciences). 
Thermal cycling was performed on an ABI Prism 7900 HT 
Sequence Detection System (Applied Biosystems). For 
all reactions, no-template controls were run, and random 
RNA preparations were also subjected to sham reverse 
transcription to verify the absence of genomic DNA 
amplification. Quantitative real-time PCR was performed 
using the SYBR green method (Bioline and Thermo 
Fisher Scientific). Thermal cycling was performed on an 
Applied Biosystems 7900 HT detection system (Applied 
Biosystems). The relative transcript level of each gene 
was normalized to the housekeeping genes cyclophilin-A 
(PPIA) and/or glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH). Primers were designed using Primer Express 
software and selected to span exon-exon junctions to 
avoid the detection of genomic DNA (primer sequences 
are provided below). 
Sequences of qRT-PCR primers, siRNAs and 
antagomir 
All primers, siRNAs and control siRNAs were 
synthesized by IDT-DNA
Gene Forward primer Reverse primer
hsa CCND1 CAATGACCCCGCACGATTTC CATGGAGGGCGGATTGGAA
hsa CCND2 CTCGAGGGATGCCAGTTGGGCC GCGGCCGCCAAAAGCGTGAATCATTGCC
has CCND3 TACCCGCCATCCATGATCG AGGCAGTCCACTTCAGTGC
has GAPDH GCATCTTCTTTTGCGTCGC CCAAATGCGTTGACTCCGA
has PPIA CCAACACAAATGGTTCCCAGT CCATGGCCTCCACAATATTCA
Name Sense strand Antisens strand
siRNA CCND2 GGCAUGAUUAGAUUGCAAAGCAATG CAUUGCUUUGCAAUCUAAUCAUGCCAU
siRNA CCND3 CUUACUGUAAUAAAGAUGAUUGUGA UCACAAUCAUCUUUAUUACAGUAGGAU
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Luciferase assay (3’-UTR reporter assays)
MDA-MB-231 cells were transfected with 30 
pmol of pre-miR-Ctrl or pre-miR-503 with 0.6 µL 
of DharmaFECT-4 (Dharmacon Research, Inc.). The 
next day, the cells were transfected with 0.1 µg of the 
psiCHECK2 vector (Promega) expressing the 3’-UTR 
of the human CCND2 mRNA (nucleotides 1-2040) 
or the mutated 3’-UTR of the human CCND2 mRNA 
(QuickChange II Site-Directed Mutagenesis Kit, 
Agilent) with JET-PEI (Polyplus transfection) according 
to the manufacturer’s instructions. The wild-type 
region of the 3’-UTR human CCND2 mRNA miR-503 
binding seed sequences were 1: 5’-GCUGCUA-3’, 2: 
5’-CGCUGCUA-3’ and 3: 5’-GCUGCUA-3’. The mutated 
region of the 3’-UTR human CCND2 mRNA miR-503 
binding seed sequence were 1: 5’-AAUAAUA-3’, 2: 
5’-CAAUUUUA-3’ and 3: 5’-AAUAAUA-3’. After 24 
h, the luciferase assay was performed using the Dual-
Luciferase Reporter Assay System (Promega). Renilla 
luciferase activity was normalized to firefly luciferase 
activity.
Data analysis
All values are expressed as the mean ± SD (in vitro 
experiments) or the mean ± SEM (patient analyses). 
Comparisons between various conditions were assessed 
using two-tailed Student’s t tests. Analyses of patients 
before and after treatments (Fig 4) were performed using 
two-tailed paired t tests. P values less than 0.05 were 
considered statistically significant.
ACKNOWLEDGMENTS
We thank Patricia Piscicelli for technical assistance. 
We thank Marie Dehuy and Christine Gilles for their 
help with luminescence analysis. We thank Julie 
Halkein, Stephanie Herkenne and Khalid Bajou for their 
expertise and Ngoc-Quynh-Nhu Nguyen for revising the 
manuscript. We would like to thank the plateform support 
staff from the Giga Research Center, Rafaat Stephan 
and Sandra Ormonese (GIGA-imaging). This study was 
supported by the University of Liège, the FRIA (Fonds 
pour la Recherche Industrielle et Agricole, Belgium), 
the FNRS (Fonds National de la Recherche Scientifique, 
Belgium), the Belgian Science Policy, the Neoangio 
program #616476 of the “Service Public de Wallonie”, 
the Fonds Léon Frédéricq and the fondation belge contre 
le cancer.
REFERENCES
1. Suzuki HI, Katsura A, Matsuyama H, Miyazono K. 
MicroRNA regulons in tumor microenvironment. 
Oncogene. 2014.
2. Goubran HA, Kotb RR, Stakiw J, Emara ME, Burnouf 
T. Regulation of tumor growth and metastasis: the role of 
tumor microenvironment. Cancer Growth Metastasis. 2014; 
7: 9–18.
3. Carmeliet P. Angiogenesis in life, disease and medicine. 
Nature. 2005; 438: 932–936.
4. Ebos JM, Kerbel RS. Antiangiogenic therapy: impact on 
invasion, disease progression, and metastasis. Nat Rev Clin 
Oncol. 2011; 8: 210–221.
5. Li M, Li J, Ding X, He M, Cheng SY. microRNA and 
cancer. AAPS J. 2010; 12: 309–317.
6. Zhang C. MicroRNAs in vascular biology and vascular 
disease. J Cardiovasc Transl Res. 2010; 3: 235–240.
7. Bartel DP. MicroRNAs: target recognition and regulatory 
functions. Cell. 2009; 136: 215–233.
8. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, 
and function. Cell. 2004; 116: 281–297.
9. Taylor DD, Gercel-Taylor C. MicroRNA signatures of 
tumor-derived exosomes as diagnostic biomarkers of 
ovarian cancer. Gynecol Oncol. 2008; 110: 13–21.
10. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, 
Lotvall JO. Exosome-mediated transfer of mRNAs and 
microRNAs is a novel mechanism of genetic exchange 
between cells. Nat Cell Biol. 2007; 9: 654–659.
11. Mathivanan S, Ji H, Simpson RJ. Exosomes: extracellular 
organelles important in intercellular communication. J 
Proteomics. 2010; 73: 1907–1920.
12. Kharaziha P, Ceder S, Li Q, Panaretakis T. Tumor cell-
derived exosomes: a message in a bottle. Biochim Biophys 
Acta. 2012; 1826: 103–111.
13. Mittelbrunn M, Gutierrez-Vazquez C, Villarroya-Beltri C, 
Gonzalez S, Sanchez-Cabo F, Gonzalez MA, Bernad A, 
Sanchez-Madrid F. Unidirectional transfer of microRNA-
loaded exosomes from T cells to antigen-presenting cells. 
Nat Commun. 2011; 2: 282.
14. Halkein J, Tabruyn SP, Ricke-Hoch M, Haghikia A, 
Nguyen NQ, Scherr M, Castermans K, Malvaux L, Lambert 
V, Thiry M, Sliwa K, Noel A, Martial JA, et al. MicroRNA-
146a is a therapeutic target and biomarker for peripartum 
cardiomyopathy. J Clin Invest. 2013; 123: 2143–2154.
15. Hergenreider E, Heydt S, Treguer K, Boettger T, Horrevoets 
AJ, Zeiher AM, Scheffer MP, Frangakis AS, Yin X, Mayr 
M, Braun T, Urbich C, Boon RA, et al. Atheroprotective 
communication between endothelial cells and smooth 
muscle cells through miRNAs. Nat Cell Biol. 2012; 14: 
249–256.
16. Wang J, Huang SK, Zhao M, Yang M, Zhong JL, Gu YY, 
Peng H, Che YQ, Huang CZ. Identification of a circulating 
microRNA signature for colorectal cancer detection. PLoS 
One. 2014; 9: e87451.
17. Freres P, Josse C, Bovy N, Boukerroucha M, Struman I, 
Bours V, Jerusalem G. Neoadjuvant chemotherapy in breast 
cancer patients induces miR-34a and miR-122 expression. J 
Oncotarget14www.impactjournals.com/oncotarget
Cell Physiol. 2014.
18. Fu Z, Qian F, Yang X, Jiang H, Chen Y, Liu S. Circulating 
miR-222 in plasma and its potential diagnostic and 
prognostic value in gastric cancer. Med Oncol. 2014; 31: 
164.
19. Kahlert C, Kalluri R. Exosomes in tumor microenvironment 
influence cancer progression and metastasis. J Mol Med 
(Berl). 2013; 91: 431–437.
20. Kucharzewska P, Belting M. Emerging roles of extracellular 
vesicles in the adaptive response of tumour cells to 
microenvironmental stress. J Extracell Vesicles. 2013; 2.
21. Webber J, Steadman R, Mason MD, Tabi Z, Clayton A. 
Cancer exosomes trigger fibroblast to myofibroblast 
differentiation. Cancer Res. 2010; 70: 9621–9630.
22. Zhuang G, Wu X, Jiang Z, Kasman I, Yao J, Guan Y, Oeh 
J, Modrusan Z, Bais C, Sampath D, Ferrara N. Tumour-
secreted miR-9 promotes endothelial cell migration and 
angiogenesis by activating the JAK-STAT pathway. EMBO 
J. 2012; 31: 3513–3523.
23. Hessvik NP, Phuyal S, Brech A, Sandvig K, Llorente A. 
Profiling of microRNAs in exosomes released from PC-3 
prostate cancer cells. Biochim Biophys Acta. 2012; 1819: 
1154–1163.
24. Carmeliet P, Jain RK. Molecular mechanisms and clinical 
applications of angiogenesis. Nature. 2011; 473: 298–307.
25. Qiu T, Zhou L, Wang T, Xu J, Wang J, Chen W, Zhou 
X, Huang Z, Zhu W, Shu Y, Liu P. miR-503 regulates the 
resistance of non-small cell lung cancer cells to cisplatin by 
targeting Bcl-2. Int J Mol Med. 2013; 32: 593–598.
26. Xiao F, Zhang W, Chen L, Chen F, Xie H, Xing C, Yu 
X, Ding S, Chen K, Guo H, Cheng J, Zheng S, Zhou 
L. MicroRNA-503 inhibits the G1/S transition by 
downregulating cyclin D3 and E2F3 in hepatocellular 
carcinoma. J Transl Med. 2013; 11: 195.
27. Yang Y, Liu L, Zhang Y, Guan H, Wu J, Zhu X, Yuan J, Li 
M. MiR-503 targets PI3K p85 and IKK-beta and suppresses 
progression of non-small cell lung cancer. Int J Cancer. 
2014; 135: 1531–1542.
28. Van Balkom BW, de Jong OG, Smits M, Brummelman J, 
den Ouden K, de Bree PM, van Eijndhoven MA, Pegtel 
DM, Stoorvogel W, Wurdinger T, Verhaar MC. Endothelial 
cells require miR-214 to secrete exosomes that suppress 
senescence and induce angiogenesis in human and mouse 
endothelial cells. Blood. 2013; 121: 3997–4006, S1–15.
29. Sharghi-Namini S, Tan E, Ong LL, Ge R, Asada HH. Dll4-
containing exosomes induce capillary sprout retraction in a 
3D microenvironment. Sci Rep. 2014; 4: 4031.
30. Lee JK, Park SR, Jung BK, Jeon YK, Lee YS, Kim MK, 
Kim YG, Jang JY, Kim CW. Exosomes derived from 
mesenchymal stem cells suppress angiogenesis by down-
regulating VEGF expression in breast cancer cells. PLoS 
One. 2013; 8: e84256.
31. Zhu W, Huang L, Li Y, Zhang X, Gu J, Yan Y, Xu X, Wang 
M, Qian H, Xu W. Exosomes derived from human bone 
marrow mesenchymal stem cells promote tumor growth in 
vivo. Cancer Lett. 2012; 315: 28–37.
32. Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, 
Tenza D, Ricciardi-Castagnoli P, Raposo G, Amigorena S. 
Eradication of established murine tumors using a novel cell-
free vaccine: dendritic cell-derived exosomes. Nat Med. 
1998; 4: 594–600.
33. Caporali A, Meloni M, Vollenkle C, Bonci D, Sala-Newby 
GB, Addis R, Spinetti G, Losa S, Masson R, Baker AH, 
Agami R, le Sage C, Condorelli G, et al. Deregulation 
of microRNA-503 contributes to diabetes mellitus-
induced impairment of endothelial function and reparative 
angiogenesis after limb ischemia. Circulation. 2011; 123: 
282–291.
34. Sarkar S, Dey BK, Dutta A. MiR-322/424 and -503 are 
induced during muscle differentiation and promote cell 
cycle quiescence and differentiation by down-regulation of 
Cdc25A. Mol Biol Cell. 2010; 21: 2138–2149.
35. Zhou B, Ma R, Si W, Li S, Xu Y, Tu X, Wang Q. 
MicroRNA-503 targets FGF2 and VEGFA and inhibits 
tumor angiogenesis and growth. Cancer Lett. 2013; 333: 
159–169.
36. Wagner-Ecker M, Schwager C, Wirkner U, Abdollahi A, 
Huber PE. MicroRNA expression after ionizing radiation 
in human endothelial cells. Radiat Oncol. 2010; 5: 25.
37. Soultati A, Mountzios G, Avgerinou C, Papaxoinis 
G, Pectasides D, Dimopoulos M-A, Papadimitriou C. 
Endothelial vascular toxicity from chemotherapeutic agents: 
preclinical evidence and clinical implications. Cancer 
Treatment Reviews. 2012; 38: 473–83.
38. Nie Y, Han BM, Liu XB, Yang JJ, Wang F, Cong XF, Chen 
X. Identification of MicroRNAs involved in hypoxia- and 
serum deprivation-induced apoptosis in mesenchymal stem 
cells. Int J Biol Sci. 2011; 7: 762–768.
39. Rissland OS, Hong SJ, Bartel DP. MicroRNA 
destabilization enables dynamic regulation of the miR-16 
family in response to cell-cycle changes. Mol Cell. 2011; 
43: 993–1004.
40. Tabruyn SP, Memet S, Ave P, Verhaeghe C, Mayo KH, 
Struman I, Martial JA, Griffioen AW. NF-kappaB activation 
in endothelial cells is critical for the activity of angiostatic 
agents. Mol Cancer Ther. 2009; 8: 2645–2654.
41. Correa de Sampaio P, Auslaender D, Krubasik D, Failla A 
V, Skepper JN, Murphy G, English WR. A heterogeneous 
in vitro three dimensional model of tumour-stroma 
interactions regulating sprouting angiogenesis. PLoS One. 
2012; 7: e30753.
